From http://www.spectrumpharm.com/sumatriptan.html on 3July2008:
On October 2004, we filed with the FDA an abbreviated new drug application (ANDA) with a paragraph IV certification, for sumatriptan succinate injection 6mg/0.5mL, seeking approval to engage in the commercial manufacture, sale, and use of the sumatriptan succinate injection product in the United States. Sumatriptan succinate is marketed by GlaxoSmithKline under the brand name Imitrex®.
On February 18, 2005, GlaxoSmithKline filed a lawsuit against Spectrum Pharmaceuticals in the United States District Court in the District of Delaware, alleging infringement of the Imitrex® patent.
In November 2006, Spectrum and GSK reached an agreement to settle the patent litigation relating to sumatriptan injection.
The terms of the confidential agreement provide that Spectrum may exclusively distribute authorized generic versions of certain sumatriptan injection products in the United States with an expected launch during GSK's sumatriptan pediatric exclusivity period which begins on August 6, 2008, but with the launch occurring not later than November 6, 2008.
Spectrum will launch sumatriptan injection through its partner for the sale and distribution of the drug, Par Pharmaceutical Companies, Inc.
Chat with our AI personalities
It'll be the end of 2008, but that is not for sure and can change. They have many other drugs with generics available by prescription that is far more prescribed than Imitrex.